DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment

Autores: Kortum, M.; Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M. ; Nooka, A. K. ; Callander, N. ; Suvannasankha, A.; Badros, A.; Libby, E. ; Trudel, S.; Richardson, P.; Sborov, D. ; Rodríguez Otero, Paula; Lonial, S. ; Zhi, E. ; Lewis, E.; Gupta, I.; Opalinska, J.